Capital Analysts LLC Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Fidelity Enhanced Mid Cap Core ETF
FMDE
|
+$62.4M |
| 2 |
ALPS O'Shares US Small-Cap Quality Dividend ETF
OUSM
|
+$36.3M |
| 3 |
State Street SPDR Portfolio Intermediate Term Corporate Bond ETF
SPIB
|
+$34.2M |
| 4 |
BlackRock Flexible Income ETF
BINC
|
+$23.1M |
| 5 |
JPMorgan Core Plus Bond ETF
JCPB
|
+$22.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Core S&P Mid-Cap ETF
IJH
|
+$56.5M |
| 2 |
State Street SPDR Portfolio S&P 600 Small Cap ETF
SPSM
|
+$39.3M |
| 3 |
iShares iBoxx $ Investment Grade Corporate Bond ETF
LQD
|
+$31.8M |
| 4 |
State Street Multi-Asset Real Return ETF
RLY
|
+$13.3M |
| 5 |
Vanguard FTSE All-World ex-US Small-Cap Index Fund
VSS
|
+$10.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 7.27% |
| 2 | Financials | 5.96% |
| 3 | Healthcare | 3.59% |
| 4 | Industrials | 2.97% |
| 5 | Energy | 2.4% |
Similar funds
Capital Analysts LLC's Q1 2025 Portfolio in Review
As of Q1 2025, Capital Analysts LLC held 1,438 positions worth $2.68B, up 7.6% from $2.49B the previous quarter. Its ten largest holdings account for 33% of the portfolio.
Capital Analysts LLC deployed $224M of net new capital in Q1 2025, opening 142 new positions and adding to 550 existing holdings. Its largest new stake was ALPS O'Shares US Small-Cap Quality Dividend ETF: 836,574 shares worth $35.2M.
By sector, the portfolio is most concentrated in Technology at 7.3% of assets, down from 8.4% a quarter earlier, followed by Financials and Healthcare.
On the sell side, the largest reduction was iShares Core S&P Mid-Cap ETF, an estimated $56.5M trimmed.
- Capital Analysts LLC's largest Q1 2025 buy was ALPS O'Shares US Small-Cap Quality Dividend ETF: 836,574 shares worth $35.2M.
- Capital Analysts LLC added most to Fidelity Enhanced Mid Cap Core ETF in Q1 2025, an estimated $62.4M increase.
- Capital Analysts LLC's biggest Q1 2025 reduction was iShares Core S&P Mid-Cap ETF, cutting an estimated $56.5M.
- Capital Analysts LLC fully exited West Pharmaceutical in Q1 2025, selling an estimated $642K.
- Capital Analysts LLC's ten largest holdings make up 33% of its $2.68B portfolio in Q1 2025.
- Capital Analysts LLC opened 142 new positions and closed 78 in Q1 2025.
- Capital Analysts LLC's portfolio value rose 7.6% quarter-over-quarter to $2.68B.
Based on Capital Analysts LLC's 13F filing for Q1 2025, filed 14 May 2025.